(Q48589819)

English

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

scientific article published on 12 September 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

1 reference

based on heuristic

inferred from title

coronary artery disease

1 reference

based on heuristic

inferred from title

Juliana Chung-ngor Chan

3

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Hertzel C. Gerstein

7

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

object named as

Richard Gray

8

0 references

Jaakko Tuomilehto

18

object named as

Jaakko Tuomilehto

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

Michał Tendera

16

object named as

Michal Tendera

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

11

object named as

John J McMurray

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

object named as

Wenying Yang

20

0 references

object named as

Duolao Wang

21

0 references

author name string

Rury R Holman

1

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Ruth L Coleman

2

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Jean-Louis Chiasson

4

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Huimei Feng

5

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Junbo Ge

6

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Yong Huo

9

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Zhihui Lang

10

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Lars Rydén

12

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Stefan Schröder

13

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Yihong Sun

14

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Michael J Theodorakis

15

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Lynne Tucker

17

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Yidong Wei

19

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Dayi Hu

22

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Changyu Pan

23

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

ACE Study Group

24

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

publication date

12 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

5

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

11

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

877-886

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Impaired Glucose Tolerance or Newly Diagnosed Diabetes Mellitus Diagnosed during Admission Adversely Affects Prognosis after Myocardial Infarction: An Observational Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

On the potential of acarbose to reduce cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to Chiasson et al.: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of nateglinide on the incidence of diabetes and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural history of impaired glucose tolerance in the Pima Indians.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Determining the most appropriate components for a composite clinical trial outcome

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(17)30309-1

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/28917545

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48589819&oldid=1631892579"